14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of adults with hormone sensitive prostate cancer.

Relugolix is recommended as an option for the treatment of adults with advanced hormone sensitive prostate cancer:

• Alongside radiotherapy for adults with high risk localised or locally advanced hormone sensitive prostate cancer
• As neo-adjuvant treatment before radiotherapy for adults with high risk localised or locally advanced hormone sensitive prostate cancer

Read NICE technology appraisal guidance